Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non-inferiority, prospective, randomised, controlled trial

Clinical and Experimental Rheumatology

Volumn 29, Issue 3, 2011, Pages 527-535

  Maheu, Emmanuel ^a   Zaim, M ^b   Appelboom, T ^c   Jeka, S ^d   Trc, T ^e   Maasalu, K ^f   Berenbaum, F ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c ERASME HOSPITAL   (Belgium)

^d Rheumatology Department   (Poland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

Author keywords

Hyaluronans; Intra articular treatment; Knee OA; Molecular weight; Non inferiority comparative trial

Indexed keywords

ANTIRHEUMATIC AGENT; F 60027; HYALURONIC ACID; STRUCTOVIAL; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HYLAN;

ADULT; AGED; ANALGESIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTRAARTICULAR DRUG ADMINISTRATION; MIDDLE AGED; MOLECULAR WEIGHT; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PROSPECTIVE STUDY;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; MOLECULAR WEIGHT; OSTEOARTHRITIS, KNEE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 80052053411     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ETHGEN O., REGINSTER J-Y: Degenerative musculoskeletal disease. Ann Rheum Dis 2004; 63: 1-3.
2. LAWRENCE R.C., HELMICK C.G., ARNETT F.C. et al.: Prevalence estimates of the arthritis and selected musculoskeletal diseases in the United States. Arthritis Rheum 1998; 41: 778-799
3. POUCHOT J., COSTE J., GUILLEMIN F.: Impact of osteoarthritis on quality of life. In: REGINSTER JY, PELLETIER JP, MARTEL-PELLETIER J, HENROTIN Y (Eds.), Osteoarthritis Clinical and Experimental Aspects. Berlin Heidelberg: Springer 1999. p 331-355,
4. ZHANG W., MOSKOWITZ R.W., NUKI G. et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus Guidelines. Osteoarthritis Cartilage 2008; 16: 137-162
5. ALTMAN R.D., HOCHBERG M.C., MOSKOWITZ R.W., SCHNITZER T.J., AND THE MEMBERS OF THE ACR SUBCOMMITTEE ON OSTEOARTHRITIS GUIDELINES: Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum 2000; 43: 1905-1915
6. JORDAN K.M., ARDEN N.K., DOHERTY M. et al.: EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-1155
7. CECCARELLI F., PERRICONE C., ALESSANDRI C. et al.: Exploratory data analysis on the effects of non pharmacological treatment for knee osteoarthritis. Clin Exp Rheumatol 2010; 28: 250-253
8. ZHANG W., ROBERTSON J., JONES A.C., DIEPPE P.A., DOHERTY M.: The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716-1723
9. LO G.H., LAVALLEY M., MCALINDON T., FELSON D.T.: Intra-articular hyaluronic acid in treatment of knee osteoarthritis: A meta-analysis. JAMA 2003; 290: 3115-3121
10. WANG C.T., LIN J., CHANG C.J., LIN Y.T., HOU S.M.: Therapeutic effect of hyaluronic acid on osteoarthritis of the knee. J Bone Joint Surg 2004; 86-A: 538-545
11. ARRICH J., PIRIBAUER F., MAD P., SCHMID D., KLAUSHOFER K., MÜLLNER M.: Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: Systematic review and meta-analysis. CMAJ 2005; 172: 1039-1043
12. BELLAMY N., CAMPBELL J., ROBINSON V., GEE T., BOURNE R., WELLS G.: Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005 Apr 18;(2): CD005321.
13. MODAWAL A., FERRER M., CHOI H.K., CASTLE J.A.: Hyaluronic acid injections relieve knee pain. J Fam Pract 2005; 54: 758-767
14. KARLSSON J., SJOGREN L.S., LOHMANDER L.S.: Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002; 41: 1240-1248
15. KARATOSUM V., UNVER B., GOCEN Z., SEN A.: Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee. A prospective, randomized, double-blind study with long-term follow-up. Clin Exp Rheumatol 2005; 23: 213-218
16. KIRCHNER M., MARSHALL D.: A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006; 14: 154-162
17. JÜNI P., REICHENBACH S., TRELLE S. et al.: Efficacy and safety of intraarticular Hylan or hyaluronic acids for osteoarthritis of the knee. Arthritis Rheum 2007; 56: 3610-3619
18. RAMAN R., DUTTA A. SHARMA HK, SHAW CJ, JOHNSON GV: Efficacy of Hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee. A prospective randomized clinical trial. Knee 2008; 15: 318-324
19. REICHENBACH S., BLANK S, RUTJES AW et al:. Hylan versus hyaluronic acid for osteoarthritis of the knee: A systematic review and meta-analysis. Arthritis Rheum 2007; 57: 1410-1418
20. French HAS (Haute Autorité de Santé) Avis de la Commission d'Évaluation des Produits et Prestations - Solutions viscoé lastiques d'acide hyaluronique pour injections intraarticulaires (gonarthrose) - Avis de la commission 25 octobre 2006 (annule et remplace celui du 06 avril 2005) http://www.has-sante.fr/portail/jcms/c-398624/solutions-viscoe-lastiques- d-acide-hyaluronique-pour-injec-tions-intra-articulaires-gonarthrose.
21. EMEA: Committee for medicinal products for human use (CHMP). Guideline on the choice of the non-inferiority margin. Doc. Ref. EMEA/CPMP/EWP/2158/99, issued London July, 27 2005.
22. ALTMAN R., ASCH E., BLOCH D. et al.: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039-1049
23. LEQUESNE M., MÉRY C., SAMSON M., GÉRARD P.: Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 1987; 65 (Suppl.): 85-89
24. KELLGREN J.K., LAWRENCE J.S.: Radiological assessment of osteoarthritis. Ann Rheum Dis 1957; 16: 494-501.
25. WARE J. JR, KOSINSKI M., KELLER S.D.: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233
26. PHAM T., VAN DER HEIJDE D., ALTMAN R.D. et al.: OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004; 12: 389-399
27. BELLAMY N., KIRWAN J., BOERS M. et al.: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Results of consensus development at OMERACTIII. J Rheumatol 1997; 24: 799-802.
28. MAHEU E., BONVARLET JP, and PARIS ASSOCIATION OF RHEUMATOLOGISTS: Acute pseudoseptic arthritis post-hyaluronane (HA) intra-articular injections. Results of a French survey in rheumatology practice (Abstract). Ann Rheum Dis 2003; 62 (Suppl. 1): 268.
29. GOLDBERG V.M., COUTTS R.D.: Pseudoseptic reactions to hylan viscosupplementation. Clin Orthop 2004; 419: 130-137
30. PULLMAN-MOOAR S., MOOAR P., SIECK M., CLAYBURNE G., SCHUMACHER H.R.: Are there distinctive inflammatory flares after hylan G-F20 intraarticular injections? J Rheumatol 2002; 29: 2611-2614